HLA frequency and prognosis in lung cancer. by Ford, C. H. et al.
Br. J. Cancer (1981) 43, 610
HLA FREQUENCY AND PROGNOSIS IN LUNG CANCER
C. H. J. FORD*, C. E. NEWMAN* AND P. MACKINTOSHt
From the *Surgical Immunology Unit, Clinical Oncology, University ofBirmingham,
Queen Elizabeth Hospital, and tTissue Typing Laboratory, Blood Transfusion Service,
Vincent Drive, Edgbaston, Birmingham
Received 8 December 1980 Accepted 26 January 1981
Summary.-In 100patients with lung cancer we havefound no significant abnormality
in overall HLA antigen frequency when compared to a control sample of 151 random
healthy individuals from the same region, though there was a high relative risk of
being HLA-BW22-positive and having lung cancer. There was an increased frequency
of HLA-B5 in small-(oat-)cell anaplastic carcinomas (P<0.05); HLA-B15 in ana-
plastic tumours (P<0.05); HLA-B40 in Stage III patients (P=0.05) and a decreased
frequency of HLA-B12 in adenocarcinomas (P<0-05). In 86 patients followed up for
21 53 years after surgery we have been unable to confirm the significant association
of HLA-AW19 and/or HLA-B5 with good prognosis as reported by others. The most
striking observation was that the frequency ofHLA-BW22 was significantly higher in
patients alive at least 21 years after surgery when compared to the control group
(P<0.05) and 83% of patients HLA-BW22-positive are alive compared to only 52 5%
of lung cancer patients lacking this antigen. However, all the P values become non-
significant when multiplied by the number of antigens studied, and these observa-
tions need further investigation in a large, prospective study.
WHEN THE RISK DATA from several
studies of HLA association with malig-
nancy are combined, there is an indication
of an association of HLA-A1 with Hodg-
kin's disease, HLA-A2 with acute lym-
phocytic leukaemia, and Sin 2 (an HLA-B
antigen) and Sin 2a (an HLA-D antigen)
with nasopharyngeal carcinoma in Singa-
pore Chinese (reviewed by Rogentine,
1979). In most ofthe studies inlung cancer,
however, no significant differences in
HLA antigen frequency have been found
at diagnosis, though there have been
several reports of HLA association with
prognosis.
In a retrospective study of 14 surgically
cured patients it was reported that HLA-
AW19 and HLA-B5 were associated with
a better prognosis (Dellon et al., 1975). In
patients who were prospectively typed
they also found a clear association of
these two antigens with prognosis in
patients with squamous or adenocar-
cinomas. This was confirmed in a 2-year
follow-up study, when patients with either
antigen had a 57% (12/21) chance ofbeing
alive and disease free 2 years after diag-
nosis, compared to only a 13% chance
(6/48) if they lacked these antigens
(Rogentine et al., 1977). This observation
has been complemented by a report of a
retrospective study of 20 patients with
non-oat-cell bronchogenic carcinoma of
the lung, alive at least 1 year after diag-
nosis, in which 50% of the survivors were
found to have one or other of these anti-
gens (Weiss et al., 1980).
However, in another report 20 retro-
spectively typed patients who had sur-
vived more than a year after surgery were
found to have an increased frequency of
HLA-B8 (Sengar et al., 1977). These
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authors also reported a decreased
frequency of HLA-A2 in the 37 patients
they studied. More recently a prospective
and retrospective study was reported in
which the frequency of HLA-B12 was
found to be raised in all patients, andHLA-
A29 was found to be raised in patients who
had died, whereas the frequency was
normal in 5-year survivors (Tongio et al.,
1980).
The aim ofthis study was to investigate
the frequency of HLA antigens in people
with bronchogenic carcinoma and to
determine whether the reported associa-
tions with prognosis applied to the lung-
cancer patients in this region.
MATERIALS AND METHODS
Patients and controls. Eighty-six patients
with lung cancer of various histological types,
who were eligible for entry into a controlled
trial of passive immunochemotherapy after
resection oftheir cancer (Newman etal., 1977),
and 14 patients with small-cell anaplastic
carcinoma of the lung who entered a pilot
study of chemotherapy and radiotherapy,
w%ere investigated. Peripheral-blood lympho-
cytes were obtained before surgery or other
therapeutic procedures and used for typing
immediately, or frozen down in liquid N2 and
stored for typing at a later date. Details ofthe
freezing, storage and thawing procedures
have been published elsewhere (Ford et al.,
1979). In cases where pre-treatment blood
samples were not available, lymphocytes
were obtained from blood samples taken
during outpatient follow-up. For the 86
patients in the immunochemotherapy study
there is a minimum follow-up of 21 years and
a maximum of 53- years after treatment.
Forty-seven of these patients are still alive
at least 2-. years after surgery. A group of 151
random healthy individuals from this district
were tested as a control group for this study.
HLA typing. Antisera recognizing 24
HLA A and B specificities were used. For
some of the antigens (e.g. AW19 and B12)
antisera defining individual sub-specificities
were used, but since not all of the patients
w-ere tested with these antisera only the main
groups have been considered in the analysis.
When there was any ambiguity in the typing
result it was repeated. The standard NIH
inicro-lyinphocytotoxic test wvas used (NIAID
Manual of Tissue Typing Techniques, 1976).
Analyses.-HLA antigen frequencies were
compared between groups by means of x2
analysis using Yate's correction. Relative
liability (Edwards, 1974) was also plotted.
RESULTS
The percentage frequencies of HLA
antigens in the 100 lung-cancer patients
and 151 controls are shown in Table I,
together with the frequency in the differ-
ent histological types. For the 86 patients
for whom there is at least a 21-year expo-
sure to risk of recurrence after surgery the
antigen frequency in those alive and dead
has been calculated, as well as the fre-
quency in Stage I and Stage III patients
(there were only 6 Stage II patients).
Comparison of the overall lung-cancer
group with the control group shows no
significant difference in the frequency of
the antigens studied, though the per-
centages differ. There were significant
differences between the lung-cancer group
and controls for: an increased frequency
of HLA-B15 in anaplastic tumours
(P < 0.05); a decreased frequency of HLA-
B12 in adenocarcinomas (P < 0.05); an
increased frequency of HLA-B5 in small-
(oat-) cell anaplastic carcinomas (P <
0.05) and an increased frequency of HLA-
B40 in Stage III patients (P= 0 05).
Although none ofthe antigens was asso-
ciated with lung cancer, from Fig. 1 it can
be seen that there is a higher relative risk
of being HLA-BW22 positive and having
lung cancer (plotting 3-fold above the
median line). The low frequency of this
antigen in the normal population (3/151)
and the small number of cancer patients
positive for HLA-BW22 (6/100) makes
this observation non-significant. However,
when the frequency of HLA-BW22 in the
47 patients alive at least 22 years after
surgery is compared with the normal popu-
lation, there is a significant increase in
the frequency of the antigen in the sur-
vivors (plotting more than 4-fold above
the median line (P < 0.05) (Fig. 2).
In Table II HLA frequency and survival
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TABLE I.-% ofHLA antigens in lung-cancer patients and controls
All Patients with a minimum follow-up
lung- Histological type* of 2j years
cancer A__
HLA Control patients ADENO ANAPL SCA SCC Total Alivet Dead$ Stage I Stage III
antigens (n=151)(n=100) (n=17) (n=15) (n=23) (n=45) (n=86) (n=47) (n=39) (n=49) (n=31)
Al 38 31 35 33 39 24 30 28 33 24 35
A2 54 50 35 40 43 62 52 53 51 51 58
A3 23 24 29 27 22 22 23 23 23 20 29
A9 15 22 29 13 26 20 22 26 18 24 16
A10 7 9 18 13 13 2 7 11 3 8 6
All 12 11 0 27 17 7 9 11 8 8 6
A28 7 2 12 0 0 0 2 2 3 4 0
AWl9 gp. 17 19 24 20 17 18 17 13 26 22 10
B5 9 12 6 7 26 9 9 9 10 6 13
B7 27 25 35 20 17 27 27 28 26 27 32
B8 26 20 24 13 22 20 20 15 26 24 16
B12 40 29 12 27 35 33 28 32 23 29 29
B13 2 3 0 0 4 4 2 2 3 2 3
B14 10 6 12 7 0 7 7 9 5 8 3
B15 11 14 6 33 9 13 14 17 10 12 16
BW16 3 6 6 13 9 2 6 4 8 4 9
B17 7 13 18 7 13 13 13 13 13 14 9
B18 5 4 18 0 0 2 5 4 5 8 0
BW21 4 6 12 0 4 7 6 4 8 4 9
BW22 2 6 6 7 0 9 7 11 3 8 6
B27 8 9 0 13 9 11 9 9 10 14 0
BW35 13 8 12 13 9 7 8 4 13 4 13
B37 2 2 0 0 0 4 2 2 3 0 6
B40 9 14 24 13 17 9 13 6 21 6 23
* ADENO =adenocarcinomas; ANAPL=anaplastic carcinomas; SCA=small-(oat-)cell anaplastic carci-
nomas; SCC =squamous-cell carcinomas.
t 8 ADENO; 10 ANAPL; 3 SCA; 26 SCC.
t 9 ADENO; 5 ANAPL; 6 SCA; 19 SCC.
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FIG. 1.-This computer diagram (Edwards, 1974) shows the relative liability to lung cancer for each
antigen and the standard error of the estimate in 100 lung-cancer patients compared with 151
controls (the sizes of the squares are proportional to the numbers ofindividuals ofeach phenotype).
are presented for antigens that others combination ofthe two are not associated
have claimed to be associated with prog- with a better prognosis than patients
nosis, as well as HLA-BW22, using a without these antigens. When only
similar format to Rogentine et al. (1977). squamous and adeno-carcinomas are con-
In the 86 patients for whom we have long- sidered, againthereis no associationwith a
term follow-up, HLA-AW19, HLA-B5 or a better prognosis. In fact, in both groups
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FIG. 2.-As Fig. 1, but comparing the survival for at least 2i years from surgery of 47 lung-cancer
patients with 151 controls.
TABLE II.-HLA and survival
Patient group
All patients (n= 86)
Squamous and adeno-
carcinomas (n=62)
All patients (n=86)
Survival
category
Alive
Dead
Antigens
AW19
AW19 B5 and/or B5 Neither
(n =16) (n =8) (n =22) (n =64)
37-5% (6)* 50% (4) 45% (10) 58% (37)
62-5% (10) 50% (4) 55% (12) 42% (27)
Alivet (n= 12)
41-7% (5)
Dead 58-3% (7)
B8
Alive (n= 17)
41% (7)
Dead 59% (10)
(n=5)
60% (3)
40% (2)
Not B8
(n=69)
58% (40)
42% (29)
(n= 15)
53-3% (8)
46-7% (7)
BW22
(n=6)
83% (5)
17% (1)
* Numbers in parantheses.
t Two are alive with recurrence, but neither are AW19- or B5-positive.
(n=47)
55-3% (26)
44-7% (21)
Not BW22
(n =80)
52-5% (42)
47-5% (38)
HLA-AW19 is associated with a worse
prognosis than that in patients lacking
this antigen (non-significant). Similarly,
in all 86patients, HLA-B8 does not appear
to be associated with a better prognosis.
Patients positive for HLA-BW22 have an
83% chance ofbeing alive at least 21 years
after surgery, compared to a 52.5%
chance for patients with other antigens.
This difference is not significant, probably
because of the small numbers of HLA-
BW22-positive individuals.
DISCUSSION
In this study we have not found any
significant deviation in antigen frequency
for lung-cancer patients when compared
to a control group from the same region.
There is an indication of an increase of
HLA-B15 in anaplastic tumours; a de-
crease of HLA-B12 in adenocarcinomas;
an increase of HLA-B5 in small-cell
anaplastic carcinomas and an increase of
HLA-B40 in Stage III patients. However,
if each P value for these significant differ-
ences is multiplied by the number of
antigens looked at, they all become non-
significant. This, together with the rela-
tively small numbers in the subgroups,
makes us very cautious in putting too
much emphasis on the apparent associa-
tions.
An interesting observation was the
increased frequency (non-significant) of
HLA-BW22 in the lung cancer group and
in particular the significant association of
this antigen with patients alive at least
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21 years after surgery. Again, if the P
value is multiplied by the number of anti-
gens looked for, it becomes non-significant.
Also, because the frequency of HLA-
BW22 is low in the normal population
(3/151) and the number of cancer patients
positive for this antigen is also small (6/
100; or 5/47 in survivors) conclusions
regarding the significance of the associa-
tion with a better prognosis must be tenta-
tive.
A second finding was that in patients
with a minimum follow-up of 21 years and
a maximum of 5- years from surgery we
have been unable to confirm the significant
association of HLA-AW19 and/or HLA-
B5 with a good prognosis, as reported by
the NIH group for squamous and adeno-
carcinomas ofthe lung (Dellon et al., 1975;
Rogentine et al., 1977) and supported by
Weiss et al. (1980). Similarly, we found no
association of HLA-B8 with better prog-
nosis in this group of patients, although
Sengar et al. (1977) have reported such an
association. The best association was seen
for HLA-BW22, when 83% of antigen-
positive individuals were alive at least 22
years after surgery compared with 52.5%
ofpatients positive for antigens other than
HLA-BW22, though this was not signi-
ficant.
Whether this lack of correlation with
other studies is due to differences in the
population studied, the size of the groups,
or the length offollow-up is unclear. Prob-
ably all three factors influence the results.
The patient population studied for prog-
nosis was heterogeneous with respect to
tumour histology. As might be expected,
there were more SCA patients in the dead
group than in those alive, but overall the
number of anaplastic, squamous and
adeno-carcinomas were similar in those
alive and dead. Four of the alive BW22-
positive patients were Stage I. However,
46% of dead patients were Stage I and
none of these were BW22-positive, so
association with a particular stage appears
unlikely.
Although the study was not performed
retrospectively it is not entirely prospec-
tive, in that not all the lymphocyte
samples were obtained before treatment.
We feel these data indicate the need for
larger, prospective studies to resolve some
of these questions, especially with regard
to HLA-BW22. Any association of an
antigen with prognosis may aid consider-
ably in our ability to tailor the treatment
to individual patients, as well as giving
a clue to genetic factors which may be
involved in susceptibility or resistance to
lung cancer. The apparent associations for
other antigens with histology and stage
would also be clarified by such studies.
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